Seeking Alpha

Thermopylaepass'  Instablog

Thermopylaepass
Send Message
I have been an active investor for the last six years. Though I started trading only large cap companies and very visible ones, I have grown to like small cap companies and IPO's. As of right now I hope to improve my investing through further experience and research. In the near future I will... More
  • Kalobios; A Lost Cause Or Great Opportunity 2 comments
    Feb 5, 2014 2:32 PM | about stocks: KBIO

    KaloBios (NASDAQ: KBIO) is a clinical stage pharmaceutical company with a number of products in the pipeline. However, the events of the last two weeks can only remind us of how clinical stage companies work, and how they might fail. The recent events also beg us to ask the question of where to go with the KaloBios stock from here. It all depends on your stake in the company, and your appetite for risk.

    What occurred in the last few weeks was a slowly climbing share price on the report on one of the clinical studies the company was doing for KB003. It was the most advanced drug in the company and the one closest to market, however, the results were disappointing and the share price has fallen by more than 40% in three days. That's to be expected as future cash flow has been delayed, diminished, and shows how the company has lost much of its potential. Now KBIO had a lagging share price anyway, but its decent rally and catastrophic collapse teach us two lessons. Clinical stage pharmaceutical companies are incredibly risky and should only take up a small amount of any portfolio. That goes for all pharmaceutical companies, especially the dozens of recent IPO's in the field. While some may be pure gold, others are not so spectacular. So that should be a well-known before investing, given the scientific, regulatory, and advertisement hurdles they have. However, the question now is, what to do with KaloBios stock?

    The easiest answer for a current investor now is to give up, dump the stock and absorb the loss. That may be practical for the mental sanity of some investors given the level of risk, however, for me, my stake in the company is relatively low, and given its fall in share price and still extensive product pipeline, I believe I may be able to recuperate part of losses faster than if I were to exit the stock and invest elsewhere, not to mention the opportunity cost of researching other equities. The mentality needed now for investors in this stock is that it will be a laggard compared to the market unless it pulls off a miracle with one of its other products. Until then you can expect a small recovery in the stock cost and a continued emphasis on the Humaneered technology platform by the company.

    My strategy for this stock is to ride a small recovery in the share price and then re-evaluate my position. Hopefully the stock will rebound modestly and then have some good news about its other clinical trials. My advice to other is that if you want to buy, consider this stock a very high risk, modest return stock. However if you already own it you may as well hope to recover some of your losses.

    Disclosure: I am long KBIO.

    Additional disclosure: I currently own 250 shares of Kalobios stock and do not plan to buy or sell any stocks or financial instruments regarding KaloBios stock within 72 hours. I also am not receiving any financial compensation from any entity for this post

    Themes: Pharmaceuticals, IPO's Stocks: KBIO
Back To Thermopylaepass' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • muloch
    , contributor
    Comments (10) | Send Message
     
    Thank you for your comment. You consider KBIO a "very high risk, modest return stock". Where does the "very high risk" come from, considering their cash on hand is exactly the current market cap? I.e. the stock trades at liquidation value, assuming their "still extensive product pipeline" and their sophisticated technology platform are completely worthless.
    6 Feb, 04:53 AM Reply Like
  • Thermopylaepass
    , contributor
    Comment (1) | Send Message
     
    Author’s reply » Assuming the company isn't liquidated immediately, the "product pipeline and sophisticated technology platform" will continue to burn the cash they still have, therefore reducing the value of the company further, the fact that the stock isn't trading at a discount and foreshadowing that trend is because their is still some value ( although greatly diminished) some investors see in the companies future earnings potential or the inherent value of the remaining products the company is developing. From the looks of things, the company is not giving up trying to be successful and develop a ground breaking drug, therefore, the high risk comes from the refusal of the company to liquidate and expend the rest of their financial capital on developing products, therefore rendering the company worthless.
    7 Feb, 05:21 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.